Eltrombopag, an oral thrombopoietin receptor agonist (TPO-RA), is an ingredient in the prescription drug Eltrombopag 25 mg. It helps lower the risk of bleeding and is mostly used to treat low platelet counts in certain medical situations. Eltrombopag is frequently used for diseases such severe aplastic anemia (SAA), hepatitis C-related thrombocytopenia, and chronic immune thrombocytopenia (ITP). In order to effectively manage these problems, Eltrombopag is essential since it stimulates the bone marrow to create more platelets.

Composition

The active pharmaceutical ingredient (API) in each Eltrombopag 25 mg tablet is 25 milligrams of Eltrombopag. Standard pharmaceutical excipients for tablet manufacturing are also included.

Mechanism of Action

Eltrombopag functions by attaching itself to and triggering the thrombopoietin receptor (TPO-R), commonly referred to as c-Mpl, found on bone marrow hematopoietic stem and progenitor cells. Megakaryocytes, the precursor cells that produce platelets, are stimulated to proliferate and differentiate as a result of this interaction. Platelet levels rise as a result, assisting individuals with thrombocytopenia in avoiding severe bleeding.

Eltrombopag attaches to a different location on the receptor than natural thrombopoietin, which enables it to function either independently or in concert. For the treatment of platelet disorders, this makes it a useful substitute or supplement to existing therapy.

Indications and Uses

Eltrombopag should be used in the following circumstances:

Adult and pediatric patients who have not responded well to corticosteroids, immunoglobulins, or splenectomy are treated with chronic immune thrombocytopenia (ITP). Eltrombopaglowers the risk of bleeding by assisting in the maintenance of a safe platelet count.

Hepatitis C-Associated Thrombocytopenia: Designed to help patients who have both thrombocytopenia and a chronic hepatitis C infection start and continue interferon-based treatment.

Severe Aplastic Anemia (SAA): Used as first-line treatment in conjunction with immunosuppressants or in individuals who have not responded adequately to immunosuppressive therapy.

Dosage and Administration

The patient’s condition, age, liver function, and reaction to medication all affect how much Eltrombopag is prescribed. Typically, 25 mg once daily is the initial dosage; platelet counts are used to alter the dosage. It’s crucial to:

Eltrombopag should be taken as prescribed by a doctor or on an empty stomach.

Dairy products and supplements containing calcium, iron, magnesium, aluminum, or selenium should not be taken with the pill as they may decrease absorption.

To guarantee safe and efficient use, platelet counts and liver function tests must be regularly monitored.

Side Effects
Although not everyone experiences them, Eltrombopag may have adverse effects like any other medicine. Typical adverse effects consist of:

Feeling queasy

Having diarrhea

A headache

Weariness

Increased liver enzyme levels

The following are serious but uncommon adverse effects:

Toxicology of the liver

Events involving thromboembolism (blood clots)

Cataracts

Fibrosis of the bone marrow (long-term usage)

Patients should notify their healthcare provider right once if they experience any odd symptoms, such as sudden leg swelling, shortness of breath, yellowing of the skin or eyes, or black urine.

Precautions and Warnings

Liver Impairment: Patients with liver illness must exercise caution. Liver function should be regularly evaluated, and dosage modifications may be required.

Thromboembolic Risk: Blood clot risk may be elevated by excessive platelet count correction. To maintain a platelet count that is just sufficient to lower the risk of bleeding, the dosage should be titrated.

Eltrombopag may interact with other drugs, particularly those that are chelated by multivalent cations, such as vitamins and antacids. Before beginning Eltrombopag, talk to your doctor about all of your current medications.

Pregnancy and Breastfeeding: It is unclear if Eltrombopag is safe to use during pregnancy or nursing. Only when the possible advantages outweigh the possible risks should it be used.

Storage
Tablets of Eltrombopag 25 mg should be kept out of direct sunlight and moisture in a cool, dry location below 30°C. Keep out of children’s reach.

Conclusion
A strong and efficient treatment for thrombocytopenia in a range of illnesses is Eltrombopag 25 mg (Eltrombopag INN). It enhances the quality of life for individuals with chronic platelet abnormalities and lowers the risk of bleeding by increasing platelet production. To reduce possible adverse effects and guarantee the best results, it must be administered under a doctor’s supervision and with the right monitoring.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. What is the purpose of Eltrombopag 25 mg?
Thrombocytopenia treatment for those with chronic or persistent immune thrombocytopenia. management of thrombocytopenia in hepatitis C infected patients. severe aplastic anemia treatment.

2. Eltrombopag: is it safe?
Serious liver issues may be brought on by or made more likely by eltrombopag.

3. How long does eltrombopag treatment last?
The median duration of eltrombopag medication was 237 days (range 14–1014 days), and the median period from ITP diagnosis was 24 months (range 6–73 months). Eltrombopag may therefore be able to be tapered gradually and eventually stopped in certain patients with chronic ITP.

4. What time of day is ideal for taking eltrombopag?
Typically, it is taken once daily on an empty stomach, either two hours after eating or at least one hour before. Every day, take eltrombopag at roughly the same time. Pay close attention to the instructions on your prescription label, and ask your pharmacist or doctor to clarify any parts you don’t understand.